Two Sigma Investments LP Increases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Two Sigma Investments LP boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,843,743 shares of the company's stock after buying an additional 863,363 shares during the period. Two Sigma Investments LP owned 1.81% of Intellia Therapeutics worth $21,498,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Teza Capital Management LLC increased its stake in Intellia Therapeutics by 74.3% during the 4th quarter. Teza Capital Management LLC now owns 26,065 shares of the company's stock worth $304,000 after buying an additional 11,107 shares in the last quarter. Tema Etfs LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $1,728,000. Second Line Capital LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $1,529,000. Shell Asset Management Co. increased its stake in Intellia Therapeutics by 45.7% during the 4th quarter. Shell Asset Management Co. now owns 29,975 shares of the company's stock worth $350,000 after buying an additional 9,403 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Intellia Therapeutics during the 4th quarter worth approximately $263,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on NTLA shares. Barclays lowered their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Guggenheim lowered their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Truist Financial lowered their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a report on Monday, April 21st. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.90.

Intellia Therapeutics Price Performance

NTLA traded up $0.37 during trading hours on Tuesday, reaching $9.53. The company's stock had a trading volume of 653,426 shares, compared to its average volume of 2,561,504. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The stock has a market cap of $986.84 million, a PE ratio of -1.76 and a beta of 2.33. The business's 50-day moving average is $7.98 and its 200-day moving average is $10.45.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. The firm's revenue for the quarter was down 42.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.12) EPS. Analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.